Christy Cox
Psychiatry · Sandusky, OHNPI 1366033599
Payments from drug & device makers
Across 646 payments — averaging $37.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$919
- Neurocrine Biosciences, Inc.$837
- Alkermes, Inc.$796
- plus $4K from 21 others
What the payments were for
- Consulting fees$2,50010%
- Speaking & faculty fees$8,60036%
- Travel & lodging$1,0514%
- Food & beverage$11,72849%
- Education$3001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $9,311 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 88 | $6,642 |
| Teva Pharmaceuticals USA, Inc. | 64 | $1,240 |
| Otsuka America Pharmaceutical, Inc. | 54 | $919 |
| Neurocrine Biosciences, Inc. | 60 | $837 |
| Alkermes, Inc. | 40 | $796 |
| Corium, LLC | 55 | $715 |
| Johnson & Johnson | 26 | $649 |
| Axsome Therapeutics, Inc. | 22 | $622 |
| Supernus Pharmaceuticals, Inc. | 13 | $469 |
| Vanda Pharmaceuticals Inc. | 17 | $328 |
| Indivior Inc. | 28 | $276 |
| Sunovion Pharmaceuticals Inc. | 17 | $235 |
| Lundbeck LLC | 13 | $225 |
| Ironshore Pharmaceuticals Inc. | 10 | $206 |
| Idorsia Pharmaceuticals US Inc | 7 | $180 |
| E.r. Squibb & Sons, L.L.C. | 6 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $112 |
| Avanir Pharmaceuticals, Inc. | 5 | $93 |
| Luye Pharma (USA) Ltd. | 3 | $65 |
| Harmony Biosciences LLC | 2 | $33 |
| Sage Therapeutics, LLC | 1 | $30 |
| Noven Therapeutics, LLC | 1 | $18 |
| GSK | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$7,375
- CAPLYTA$4,895
- QELBREE$251
- Austedo XR$249
- INVEGA SUSTENNA$225
- INVEGA TRINZA$225
- UZEDY$125
- Auvelity$124
- Azstarys$123
- REXULTI$122
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- QUVIVIQ$104
How this compares
$24,179 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $243,108 |
| VraylarCariprazine Hcl | 67 | $98,679 |
| Austedo XrDeutetrabenazine | 12 | $80,862 |
| RexultiBrexpiprazole | 41 | $67,049 |
| CaplytaLumateperone Tosylate | 24 | $49,524 |
| Lurasidone Hcl | 114 | $42,064 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $36,724 |
| TrintellixVortioxetine Hydrobromide | 16 | $10,550 |
| Aripiprazole | 114 | $8,352 |
| Chlorpromazine Hcl | 15 | $6,994 |
| Atomoxetine Hcl | 36 | $6,775 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,813 |
| Quetiapine Fumarate | 189 | $3,687 |
| DayvigoLemborexant | 11 | $3,619 |
| Asenapine Maleate | 16 | $3,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $837 | $243,10829 claims |
| AbbVieVraylar | $9,311 | $98,67967 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,240 | $80,86212 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $919 | $67,04941 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $6,642 | $49,52424 claims |
| Axsome Therapeutics, Inc.Auvelity | $622 | $36,72427 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $112 | $14,36227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Sandusky
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.